














1512Blood, and Not Urine, BK Viral Load Predicts Renal
Outcome in Children with Hemorrhagic Cystitis
following Hematopoietic Stem Cell Transplantation
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Stella M. Davies,1 Hong J. Yin,3 Julia Lawrence,4 Parinda A. Mehta,1
Jack J. Bleesing,1 Alexandra H. Filipovich,1 Rebecca A. Marsh,1 Sonata Jodele1BK virus is a significant cause of hemorrhagic cystitis after hematopoietic stem cell transplantation (HSCT).
However, its role in nephropathy post-HSCT is less studied. We retrospectively evaluated clinical outcomes
in pediatric HSCT patients with hemorrhagic cystitis. Although most of these patients had very high urine BK
viral loads (viruria), patients with higher BK plasma loads (viremia) had significant renal dysfunction, a worse
clinical course, and decreased survival. Patients with a peak plasma BK viral load of.10,000 copies/mL (high
viremia) were more likely to need dialysis and aggressive treatment for hemorrhagic cystitis compared to
patients with #10,000 copies/mL (low viremia). Conversely, most patients with low viremia had only tran-
sient elevations in creatinine, and less severe hemorrhagic cystitis that resolved with supportive therapy.
Overall survival (OS) at 1 year post-HSCTwas 89% in the low viremia group and 48% in the high viremia
group. We conclude that the degree of BK viremia, and not viruria, may predict renal, urologic, and overall
outcome in the post-HSCT population.
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BK is a polyomaDNA virus that infects 90% of the
population by adulthood and remains dormant in the
uroepithelial cells of immune-competent hosts [1].
During periods of immunosuppression, such as fol-
lowing solid organ or hematopoietic stem cell trans-
plantation (HSCT), BK reactivation may lead to
organ dysfunction [1]. BK virus is a known cause of
nephropathy following renal transplantation [2], but
in HSCT recipients, it has generally been associated
with isolated hemorrhagic cystitis [3]. However,
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HSCT patients [4-7].
Urine and blood specimens can be monitored for
BK virus using quantitative polymerase chain reaction
(PCR) assays [8,9]. Using viruria (detection of virus in
the urine) to assess for nephropathy is problematic,
given the high rates of hemorrhagic cystitis and
asymptomatic urinary shedding in the post-HSCTpop-
ulation [3,10,11]. Although only a small percentage of
viruric renal transplant patients will develop viremia or
overt nephropathy [12], the relationship between viruria
and viremia has yet to be characterized in HSCT
patients.
Given the limitations of interpreting viruria, mon-
itoring only BK viremia was recently shown to be cost-
efficient after pediatric renal transplantation [13]. This
practice has also been supported by adult kidney trans-
plant guidelines [14]. Despite the growing literature in
renal transplantation, there are few studies assessing
BK viremia in the HSCT setting [15,16]. Finally,
there are no current guidelines for the monitoring
and treatment of BK virus infection after HSCT.
We report a retrospective evaluation of the clinical
impact of BK viruria, viremia, and the prevalence of as-
sociated nephropathy in a pediatric HSCTpopulation.
Our data emphasize the importance of plasma BK
Biol Blood Marrow Transplant 17:1512-1519, 2011 1513BK Viremia after HSCTmeasurements in predicting renal, urologic, and over-
all clinical outcomes.METHODS
We retrospectively reviewed the charts of all pedi-
atric patients undergoing HSCT at Cincinnati Chil-
dren’s Hospital Medical Center (CCHMC) in the
past 3.5 years, after institutional review board approval
was obtained. The goal of the study was to evaluate the
clinical impact of viremia and viruria in HSCT pa-
tients, and to assess the occurrence of BK-virus associ-
ated nephropathy. BK studies were performed in
patients with hematuria or cystitis, and not as routine
post-HSCT screening. Patient records were reviewed
for evidence of hematuria or cystitis from January 2007
to June 2010, as BK PCR testing first became available
for clinical use at our center in 2007. Hematuria was
defined as .5 red blood cells per high-powered field
(on microscopic analysis automatically triggered by
a positive dipstick for blood) or documented gross he-
maturia with or without symptoms of cystitis (dysuria,
urgency, bladder pain/spasms). Laboratory studies for
plasma and urine viral PCRs were also reviewed in the
asymptomatic HSCT population to ensure complete-
ness of case identification.
Pathogens related to the development of hemor-
rhagic cystitis were recorded. Patients having at least
1 urine or plasma BK PCR were included in the pri-
mary analysis. Quantitative BK virus PCR performed
on plasma or urine samples had a detection threshold
level of 1200 copies/mL. The maximum BK viral
load in plasma and urine was documented. Patients
with BK viremia were assigned to either the high viremia
group (maximum BK viral load .10,000 copies/mL)
or the low viremia group (maximum BK viral load
#10,000 copies/mL). This cutoff level was based on
the kidney transplant literature [12].
Transplant data, including complications and rou-
tine clinical and laboratory information, was collected
for the identified cohort. Renal function was assessed
by serum creatinine and pre-HSCT nuclear glomeru-
lar filtration rate (nucGFR), and compared to changes
in serum creatinine after the diagnosis of BK virus
infection. The maximum fold increase in serum creat-
inine from the pre-HSCT value was calculated by
dividing the highest creatinine after BK virus detection
by pre-HSCT creatinine value. Renal biopsy informa-
tion, if available, was also reviewed.
As there are no uniform guidelines for BK virus
therapy following HSCT, we recorded treatments
and medications prescribed at the discretion of the at-
tending physician. Standard supportiveHSCT care in-
cluded pneumocystis pneumonia, fungal prophylaxis,
and acyclovir prophylaxis if either recipient or donor
was seropositive for cytomegalovirus (CMV) or herpessimplex virus (HSV). Intravenous immunoglobulin
(IVIG) was provided to all patients to maintain a nor-
mal immunoglobulin level for age. Routine weekly vi-
ral monitoring included blood PCR testing for CMV,
Epstein-Barr virus (EBV), and adenovirus.
Graft-versus-host disease (GVHD) was graded ac-
cording to the Glucksberg criteria [17]. Transplant-
associated thrombotic microangiopathy (TA-TMA)
was diagnosed based on currently accepted criteria in-
cluding: de novo microangiopathic anemia (elevated
lactate dehydrogenase [LDH], decline in hemoglobin
and platelets, evidence of schistocytes on peripheral
blood smear, decreased haptoglobin), and impaired
renal or neurologic function [18,19].RESULTS
Characteristics of the Study Population
A total of 314 HSCTs were performed during the
evaluation period (January 2007 to June 2010).
Thirty-five HSCT patients (11%) had documented
hemorrhagic cystitis. Urine was tested for BK virus in
33 of these 35 patients, and was positive in 30 (91%).
One of the 2 patients had a positive plasma BK test
without urine evaluation for BK virus, and the other pa-
tient had no documented infections and was not evalu-
ated for BK virus. The mean urine BK viral load in all
patients with viruria was 8 billion copies/mL with
73% (22/30) of patients having a maximum urine viral
load.1 billion copies/mL. Sixty percent (21/35) of pa-
tients with hemorrhagic cystitis had plasma BK virus
tested, and all of them had viremia. Of these 21 patients,
10 patients had high viremia (.10,000 copies/mL,
ranging from 16 thousand to 30 billion copies/
mL) and 11 patients had low viremia (#10,000 copies/
mL, ranging from 1.25 to 9 thousand copies/mL).
The transplant characteristics of the 21 patients
with viremia are summarized in Table 1. All but 1 pa-
tient underwent allogeneic HSCT. The majority of al-
logeneic transplants were from unrelated donors (17/
20, 85%). Bone marrow was the main source of stem
cells (18/21, 86%). A total of 4 patients, 3 of whom
were in the high viremia group, received reduced-
intensity conditioning regimens, and all others
received myeloablative conditioning regimens.Transplant Comorbidities: GVHD, TA-TMA,
and Other Viral Infections
Most patients in both groups received cyclosporine
and methylprednisolone (1-2 mg/kg/day) for GVHD
prophylaxis. The prevalence of acute GVHD
(aGVHD) was similar in the high viremia (7/9, 78%)
and low viremia (8/11, 73%) groups, with 22% of
patients in the high viremia group and 36% in the
low viremia group having acute grade 3 GVHD.








Mean age at transplant (years) 13 11.2
Sex




0 (0%) 3 (27%)
NEMO 1 (10%) 2 (18%)
Fanconi anemia 2 (20%) 0 (0%)
CML 2 (20%) 0 (0%)
HLH 0 (0%) 2 (18%)
Medulloblastoma 1 (10%) 0 (0%)
XLP1 1 (10%) 0 (0%)
Myelodysplastic syndrome 1 (10%) 0 (0%)
Congenital neutropenia 1 (10%) 0 (0%)
CVID 1 (10%) 0 (0%)
Metachromatic
leukodystrophy
0 (0%) 1 (9%)
Adrenoleukodystrophy 0 (0%) 1 (9%)
X-linked Hyper IgM 0 (0%) 1 (9%)
AML 0 (0%) 1 (9%)
Transplant type
Allogeneic 9 (90%) 11 (100%)
Autologous 1 (10%) 0 (0%)
Donor type
Matched unrelated 4 (40%) 6 (55%)
Mismatched unrelated 3 (30%) 4 (36%)
Matched sibling 2 (20%) 1 (9%)
Autologous 1 (10%) 0 (0%)
Stem cell source
Bone marrow 8 (80%) 10 (91%)
PBSC 2 (20%) 1 (9%)
Transplant chemotherapy
Myeloablative 7 (70%) 10 (91%)
Reduced intensity 3 (30%) 1 (9%)
BMT regimens:
Bu/Cy/ATG 4 (40%) 10 (91%)
Campath/Flu/Mel 3 (30%) 1 (9%)
Flu/ATG 1 (10%) 0 (0%)
Cy/Bu/Flu/ATG 1 (10%) 0 (0%)
Bu/Mel/Thio/A 1 (10%) 0 (0%)
Bu indicates busulfan; Cy, cyclophosphamide; ATG, antithymocyte glob-
ulin; Flu, fludarabine; Mel, melphalan; Thio, thiotepa; A, amifostine (che-
moprotectant); HSCT, hematopoietic stem cell transplant; AML, acute
myelogenous leukemia; PBSC, peripheral blood stem cell; CML, chronic
myeloid leukemia; CVID, common variable immunodeficiency; HLH,
hemophagocytic lymphohistiocytosis.
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of 7 (71%) patients in the high viremia group and in 5
of 8 (63%) patients in the low viremia group. Eighty-
nine percent of patients in the high viremia group
and 100%of patients in the low viremia group received
methylprednisolone .2 mg/kg/day for GVHD ther-
apy. Additional immunosuppressive therapy, mainly
with monoclonal antibodies, was given to 6 of 7
(86%) patients with GVHD in the high viremia group
and to 5 of 8 (63%) patients in the low viremia group.
Of note, more patients in the high viremia group re-
ceived infliximab (78% versus 36%) and basiliximab
(33% versus 9%). Mycophenolate (MMF) was used
in 4/10 (40%) of patients with high viremia and 2/11(18%) of patients with low viremia. GVHD was the
cause of death in 1 patient in each group.
Seven of 10 (70%) patients in the high viremia
group were diagnosed with transplant-associated
thrombotic microangiopathy (TA-TMA) during BK
viremia, whereas only 2 of 11 (18%) patients in the
low viremia group had a concomitant diagnosis of
TA-TMA. All patients with TA-TMA had significant
hypertension requiring intensive medical therapy.
Three patients in the high viremia group had renal
biopsies diagnostic for BK virus–associated nephropa-
thy. One of them also had histologic evidence of
TA-TMA on the same biopsy specimen (Figure 1).
In terms of coincident viral infections, 2 patients in
the high viremia group had intermittent CMV and
EBV viremia (treated with ganciclovir, foscarnet, cido-
fovir, rituximab) and 1 patient also developed adeno-
viremia. One patient in the low viremia group had
CMV viremia and retinitis (treated with ganciclovir,
foscarnet, cidofovir).Renal, Urologic, and Overall Outcome
Hemorrhagic cystitis presented at a similar time
post-HSCT in the high and low viremia groups (me-
dian 33 and 31 days post-HSCT). Eighty percent of
patients in both viremia groups had very high urine
viral loads of .1 billion copies/mL (Table 2). The
lag time between presentation of hemorrhagic cystitis
and the first documented positive urine BK PCR was
\7 days in 80% of patients in both groups. The lag
time between the first documented viruria and the first
documented viremia was\7 days in 80% of patients
with high viremia and 64% of patients with low vire-
mia. Twenty of 21 (95%) patients were either receiving
corticosteroids or had discontinued them within the
previous 3 weeks prior to the onset of BK viruria.
Clinical outcomes are summarized in Table 2. The
majority of patients with BK infection presented with
gross hematuria, with only 3 patients in the high
viremia group and 2 patients in the low viremia group
having microscopic hematuria. Five patients, all in the
high viremia group, required aggressive surgical inter-
ventions for obstructive uropathy. One patient under-
went bilateral nephrostomy tube placement and had
multiple procedures to evacuate bladder clots. None of
the patients in the low viremia group required surgical
intervention for management of hemorrhagic cystitis.
All 21 patients with viremia had baseline pre-
HSCT creatinine that was normal for age, and all
but 1 patient had baseline nucGFR .70 mL/min/1.73
m2. Patients with high viremia developed more signif-
icant impairment of renal function compared to those
with low viremia. Specifically, patients in the high vire-
mia group had a significantly higher serum creatinine
elevation after BK virus detection (P\ 0.02) in com-
parison to their pre-HSCT baseline. Patients with
Figure 1. Renal biopsy in patient with BK infection and TA-TMA: renal biopsy showed mild inflammatory infiltrate in the interstitium, mild interstitial
fibrosis, and tubular atrophy. Most of the capillaries were patent, but with focal segmental mild thickening of glomerular capillary walls with a double
contour appearance (A, trichrome stain, 60), consistent with expansion of the subendothelial zone. Electron microscopy showed irregular
electron-lucent expansion of the subendothelial zone (double arrows) because of acute endothelial cell damage with neo-membrane formation. The
capillary lumen was occluded by thrombi (B). With no immunoglobulin deposition, these changes are diagnostic for thrombotic microangiopathy.
Many tubular epithelial cells had large, homogenous, intranuclear inclusions (arrows) with a ground-glass appearance (C, H&E, 40), representing ag-
gregations of viral particles in the nucleus. BK virus in situ hybridization demonstrated positive staining in the nucleus (D, 40). Electron microscopic
study also revealed 40- to 45-nm electron-dense virions in the nucleus (not shown).
Biol Blood Marrow Transplant 17:1512-1519, 2011 1515BK Viremia after HSCTlow viremia also had creatinine elevations compared to
their pre-HSCT baseline, but elevations were lower
and transient, resolving with supportive care (Table 2).
Seven of 10 patients (70%) in the high viremia
group required renal replacement therapy (RRT). Six
of these patients progressed to end-stage renal disease
(ESRD), and 1 remains with stage 2 chronic renal
disease (CKD). Four patients with ESRD died, andTable 2. Clinical Outcomes in 21 HSCT Patients with BK Viremia
High Virem
Copies/m
Urine BK >1 billion copies/mL 8 (8
Obstructive uropathy requiring surgical intervention 5 (5
Average max. fold increase in creatinine from pre-SCT 6
TA-TMA 7 (7
Renal replacement therapy 7 (7
Biopsy proven polyoma virus–associated nephropathy 3/3 sa
End-stage renal disease 6 (5
Mortality attributed to BK virus 3 (3
TA-TMA indicates transplant-associated thrombotic microangiopathy; HSCT,
*Unconditional exact test, two-sided.
†Wilcoxon two-sample test.
‡Not attributed to polyoma virus–associated nephropathy.2 patients remain on RRT 717 and 536 days after
HSCT. One patient in the low viremia group received
RRT for 2 days prior to death from acute multiorgan
failure secondary to GVHD and fungal infection.
Overall survival (OS) at 100 days and 1 year post-
HSCT in the low viremia group was 100% and 89%,
respectively, and in the high viremia group was 90%
and 48%, respectively (Figure 2). Confidence intervalsia: >10,000
L (n 5 10)
Low Viremia: #10,000
Copies/mL (n 5 11) P Value
0%) 8 (80%) (n 5 10) >0.99*
0%) 0 (0%) 0.009*
.4 2.1 0.02†
0%) 2 (18%) 0.03*
0%) 1 (9%)‡ 0.006*
mples none done n/a
0%) 0 (0%) 0.003*
0%) 0 (0%) 0.08*
hematopoietic stem cell transplantation; SCT, stem cell transplant.
1516 Biol Blood Marrow Transplant 17:1512-1519, 2011H. L. Haines et al.were not calculated because of the small sample size
and high censoring rate. Three of 6 deaths (50%) in
the high viremia group were attributed to BK virus in-
fection, including the only patient who died before 100
days post-bone marrow transplant (BMT) (day 198).
Plasma viral load at the time of death for these 3 patients
was 30 billion copies/mL, 950 million copies/mL, and
340 million copies/mL. The other 3 patients in the
high viremia group died from multiorgan failure,
pneumocystis pneumonia (both after resolution of
BK viremia), and aGVHD (with a BK virus load of
104 million copies/mL at the time of death). One pa-
tient in the low viremia group died, secondary to
aGVHD and fungal infection. None of these patients
had primary disease relapse, or graft failure.
BK Virus–Directed Therapy
Sixty percent of patients in the high viremia group
and 55% of patients in the low viremia group received
cidofovir to treat BK virus infection. The decision to
use cidofovir was at the discretion of the attending phy-
sician, and based on severity of clinical symptoms asso-
ciated with BK virus infection, or for coinfections with
CMVor adenovirus.Ninety-twopercent of all cidofovir
doses administered for BK infection were 1 mg/kg/day
(with saline hydration and without probenecid) given 1
to 3 times per week. This dosing regimen was based on
pediatric renal and adult HSCT literature described in
the discussion. The average weekly dose was 1.1 mg/
kg in the high viremia group and 1.4 mg/kg in the low
viremia group. The median number of cidofovir doses
given over the course of therapy was 15 (range: 4-39)
in the high viremia group and 3.5 (range: 2-57) in theFigure 2. Overall survival (OS) after HSCT according to BK viremia
level. Kaplan-Meier estimated OS was calculated starting from HSCT
date (day 0, or stem cell infusion date) till the last date of contact or
death for patients with low BK viremia (#10,000 copies/mL) and pa-
tients with high BK viremia (.10,000 copies/mL). Vertical hatched lines
represent day 1100 and day 1365 following HSCT.low viremia group. The median cumulative cidofovir
dose was 7.5 mg/kg (range: 0-75) in the high viremia
group and 2 mg/kg (range: 0-55) in the low viremia
group, with 2 patients in the high viremia group receiv-
ing 4 and 6 weekly doses of 5 mg/kg/dose and 1 patient
in the low viremia group receiving 5 weekly doses of
5 mg/kg/dose for viral coinfections. Probenecid pro-
phylaxis and saline hydration was used for 5 mg/kg/
dose cidofovir dosing. Two of 10 (20%) patients in
the high viremia group and 4 of 11 (36%) patients in
the low viremia group had documented BK viremia
resolutionby plasmaPCR.All other patients haddetect-
able viremia on the last available plasma PCR.
One patient in the high viremia group received
therapy with intravesical prostaglandins and intravesi-
cal cidofovir without any improvement. A second pa-
tient in the high viremia group was treated with
intravenous estrogen for severe hemorrhagic cystitis
with a partial response (50% reduction in PRBC trans-
fusion requirements).DISCUSSION
BK virus is an increasingly recognized cause of
significant complications following HSCT [16,20-22].
BK virus reactivation during periods of immunosup-
pression can be associated with significant organ
dysfunction, most commonly in the lower urinary tract
and kidneys [2]. BK-associated hemorrhagic cystitis is
rare after renal transplantation, but this complication
is common after HSCT [10]. The reason for this differ-
ence is not known, but may be related to cyclophospha-
mide exposure or GVHD (which leads to profound
immune suppression) in the HSCT population
[21,23,24]. Earlier renal transplant literature associated
MMF with a higher rate of BK nephropathy [25]; how-
ever, more recent reviews suggest that the depth of over-
all immune suppression is more important than the
particular immunosuppressant agent [1,26]. This
correlation with MMF has not been described in
HSCT patients, and less than one-third of patients in
our cohort received MMF, limiting any conclusions.
Similarly, even thoughmore patients in the high viremia
group received basiliximab and infliximab, the small
numbers of patients receiving these monoclonal anti-
bodies preclude any correlation between these medica-
tions and severity of BK virus infection.
BK virus infection after HSCT can be diagnosed
with urine PCR testing. Several studies have correlated
quantitative urinary viral loads with the severity of
hemorrhagic cystitis. Not surprisingly, patients with
higher, sustained levels of viruria were more likely to
be diagnosed with hemorrhagic cystitis and have
a worse outcome [16,27].
The relationship between viremia, nephropathy,
and overall outcome has been well documented after
Biol Blood Marrow Transplant 17:1512-1519, 2011 1517BK Viremia after HSCTrenal transplant [1,12,28] but is less understood in
HSCT patients [6]. Erard et al. [15] found that
HSCT patients with a BK plasma load .10,000 cop-
ies/mL had a higher rate of hemorrhagic cystitis. In
2009, O’Donnell et al. [16] prospectively found that
prolonged BK viremia was an independent risk factor
for the development of post-HSCT renal impairment,
but these authors did not report any correlation be-
tween plasma viral load and outcome.
In the present study, we found that urine BK levels
did not correlate with clinical prognosis, as almost all
our patients with hemorrhagic cystitis had very high
levels of viruria, but did not necessarily have a poor
outcome. However, in agreement with O’Donnell
et al. [16], we found that patients with viremia had im-
paired renal function after diagnosis. Expanding on
their findings, we demonstrated that a BK plasma level
of 10,000 copies/mL could differentiate patients with
a poor renal, urologic, and overall outcome from those
with a self-limited, milder course. Specifically, al-
though all patients with viruria who were evaluated
with BK plasma PCR had viremia, patients in the
high viremia group had worse renal function, a greater
need for dialysis, more aggressive surgical interven-
tions for hemorrhagic cystitis, and a higher mortality
compared to patients in the low viremia group. This
10,000 copy/mL cutoff level has also been shown to
predict the development of nephropathy after kidney
transplant [12].
It is important to note that renal dysfunction fol-
lowing HSCT is multifactorial. Hemorrhagic cystitis
can lead to renal insufficiency via urinary tract obstruc-
tion. Nephrotoxic medication use is common follow-
ing HSCT and includes chemotherapy, calcineurin
inhibitors, antibiotics, and even antiviral therapy with
cidofovir for BK virus infection. Furthermore, com-
plications such as aGVHD and TA-TMA are also
associated with significant short- and long-term renal
impairment [29]. Interestingly, 70% of our patients
in the high viremia group were also diagnosed with
TA-TMA during periods of BK viremia. Viral infec-
tions associated with the development of TA-TMA
include CMV, adenovirus, HHV-6, and parvovirus
B19 [18,30-33]. To the best of our knowledge, there
are only 3 reports of TA-TMA associated with BK virus
infection [7,34,35]. Even though BK virus traditionally
damages renal tubular cells and TA-TMA affects the
glomerular endothelium, we found both of these pro-
cesses occurring concomitantly (Figure 1). Although
this association could merely be coincidental, it is pos-
sible that BK virus is a novel trigger for TA-TMA,
contributing to the severe renal injury observed in
our high viremia group patients.
The optimal treatment for BK associated hemor-
rhagic cystitis or nephropathy in HSCT patients is
currently not known. Treatment for hemorrhagic cys-
titis is generally supportive and includes pain control,transfusion support, intravenous fluids, and bladder ir-
rigations to prevent urinary tract obstruction [23].
Cidofovir, or (S)-1-(3-hydroxy-2-phosphonylme-
thoxypropyl) cytosine, is a broad-spectrum anti-DNA
virus agent active against CMV, adenovirus, and BK
virus, and exhibits dose-related nephrotoxicity, limit-
ing its widespread use. High-dose cidofovir therapy
(3-5 mg/kg/dose) prescribed for CMV and adenovi-
rus infections requires probenecid administration
for renal function protection via reduction of intra-
cellular accumulation of cidofovirphosphocoline in
the proximal tubule. Intermediate-dose cidofovir (1
mg/kg/dose) every 1 to 3 weeks with saline hydration
and without probenecid prophylaxis had been suc-
cessfully used in pediatric renal transplant patients
with BK-associated nephropathy [36,37]. All these
patients had impaired renal function when cidofovir
was initiated. These studies demonstrated that
cidofovir at this dose was effective in reducing BK
viremia without further deterioration or even with
improvement in renal function. Ganguly et al. [38]
and Savona et al. [39] each reported a series of adult
HSCT patients with hemorrhagic cystitis and BK vi-
remia treated with intermediate-dose cidofovir regi-
mens weekly. In these patients, there was no
creatinine increase, and approximately 70% of pa-
tients had a decrease in viruria. As there is no well-
established cidofovir dosing regimen for BK infection
in pediatric HSCT patients, our patients were treated
with intermediate-dose cidofovir based on the above
outlined data. Even though cidofovir-related nephro-
toxicity cannot be excluded, renal biopsies obtained
in our patients with high BK viremia demonstrate
BK virus inclusions in tubules and/or glomerular
injury from TA-TMA, supporting pathogenesis of
renal injury other than medication induced.
Well-designed trials of other potential antiviral
therapies, including leflunomide, ciprofloxacin, and
intravenous immune globulin have not been per-
formed. A reduction in immunosuppression, first-line
therapy for BK allograft nephropathy after renal trans-
plant, is effective to control BK virus infection in that
clinical setting [40], but is often not feasible post-
HSCT because of the risk of GVHD. Illustrating
this point, in our cohort, BK virus infection often fol-
lowed a diagnosis of GVHD, where immunosuppres-
sion is increased. Leflunomide, an antimetabolite
with antiviral and immunosuppressive properties,
might be an attractive option for patients with BK vi-
remia and GVHD [41]. Leflunomide is also effective
against CMV and might be indicated in CMV- and
BK virus–infected patients [42]. Significance of myelo-
suppressive effects of leflunomide had not yet been
evaluated in HSCT patients. There are reports of
thrombotic microangiopathy in renal transplant pa-
tients receiving leflunomide, soHSCT patients receiv-
ing leflunomide should be monitored for TA-TMA
1518 Biol Blood Marrow Transplant 17:1512-1519, 2011H. L. Haines et al.[43]. However, it is plausible that TA-TMA may be
triggered not by leflunomide, but by BK virus itself,
a possibility supported by the fact that none of our pa-
tients with TA-TMA had received leflunomide.
Our study is limited by its retrospective design and
BK diagnostic testing in only symptomatic patients.
We found a very high prevalence (∼90%) of BK virus
infection in those with hemorrhagic cystitis. Although
most patients with hemorrhagic cystitis had high urine
viral loads, those with high levels of viremia (.10,000
copies/mL) had worse outcomes.
Based on our results, we advocate a single urine BK
PCR test to confirm the viral etiology in patients with
clinical concern for hemorrhagic cystitis. Following
a positive urine test, plasma BK viral monitoring may
assist with prognosis and guide the use of antiviral
therapies. Furthermore, BK plasma testing should be
considered for HSCT patients with unexplained renal
dysfunction, even in the absence of obvious hemor-
rhagic cystitis. Prospective clinical trials are urgently
needed to confirm our findings, determine the poten-
tial role of TA-TMA andGVHD inHSCT-associated
BK infection and nephropathy, and establish optimal
monitoring and treatment protocols.ACKNOWLEDGMENTS
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